|Dr. Roger James Pomerantz FACP, M.D., F.A.C.P.||Chairman, CEO & Pres||65k||N/A||1957|
|Ms. Natalie Bogdanos J.D.||Gen. Counsel, Corp. Sec. & Data Protection Officer||540.63k||N/A||1969|
|Dr. Cara Cassino||Chief Medical Officer and Exec. VP of R&D||766.14k||N/A||1962|
|Mr. Michael Messinger CPA, CPA||CFO & Chief Accounting Officer||N/A||N/A||1975|
|Ms. Nancy Dong||VP of Fin. & Admin.||N/A||N/A||1965|
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
ContraFect Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.